News and features
Read the latest news and features about our world-leading research, discoveries, fundraising and philanthropy. If you want to keep updated on our news, you can follow us on social media or sign up for our Search newsletter.
If you’re a journalist and want to find out more, you can contact our media relations team.
-carousel-945x581.jpg?sfvrsn=d29fb9e9_2 "A high magnification image of ovarian clear cell carcinoma (photo: Nephron) carousel 945x581")
Newly identified biomarker could improve treatment for people with rare type of ovarian cancer
Scientists at The Institute of Cancer Research, London, have identified a gene that affects how ovarian clear cell carcinoma (OCCC) could respond to a new class of drug called ATR inhibitors.
Scientists develop new tool to beat cancer’s survival tactics
Scientists have developed a tool which helps them better understand cancer’s survival tactics – and could eventually lead to new treatments for dozens of cancer types.
Scientists discover the ‘roadmap’ that aggressive cancer uses to spread around the body – identifying ways to block its escape
Scientists have discovered a new way to predict which tumours will become aggressive before they metastasise and spread around the body.
.png?sfvrsn=110bfd2c_1 "New data tool could bring RNA sequencing into standard clinical practice, improving diagnosis and treatmentArticles Hero Banner (2)")
New data tool could bring RNA sequencing into standard clinical practice, improving diagnosis and treatment
Researchers have developed a new tool that could help clinicians diagnose the most common type of breast cancer more accurately and make better treatment decisions.
ICR welcomes NICE recommendation of olaparib for advanced breast cancer
The Institute of Cancer Research, London, strongly welcomes the decision by NICE to recommend that the targeted drug olaparib can be used for locally advanced or metastatic breast cancer.
New understanding of aggressive form of breast cancer paves the way for tests and treatments
Scientists have developed a machine learning tool that can predict how an aggressive type of breast cancer will respond to treatment, and when it will return.
Scientific achievements of 2024
We've selected a range of discoveries from 2023/24 – chosen because they illustrate the quality and breadth of our basic, translational and clinical research and our ambitions under the ICR's research strategy.
Powerful new therapy doubles progression-free survival in advanced breast cancer
A three-drug combination for aggressive advanced breast cancer doubles the length of time before the cancer progresses, compared with a drug combination currently available on the NHS, new research has shown.
Professor Axel Behrens elected as Fellow of the Academy of Medical Sciences
Professor Axel Behrens, Scientific Director of the Cancer Research UK Convergence Science Centre and leader of the Cancer Stem Cell Group at The Institute of Cancer Research, London, has been awarded a prestigious Fellowship by the Academy of Medical Sciences.
Researchers identify what drives PARP inhibitor resistance in advanced breast cancer
Researchers at The Institute of Cancer Research, London, have increased our understanding of how a cancer drug called a PARP inhibitor stops working in women with breast cancer that has spread. This research could ultimately help predict who’s more likely to respond to these drugs, and could lead to more effective ways to treat the disease.
Research uncovers how to target ‘sleeping’ breast cancer cells and prevent relapse
Scientists have discovered how breast cancer cells can ‘hibernate’ to avoid treatment and ‘wake up’ years later – causing a relapse that is more difficult to treat.
.jpg?sfvrsn=b8be1e0b_2 "breast cancer cell 547x410 (1)")
Targeted immunotherapy could lead to pioneering treatment for breast cancer
A new type of immunotherapy that targets non-cancer cells could help prevent the growth and spread of breast cancer tumours, according to new research from the ICR.
